Docoh
Loading...

KPTI Karyopharm Therapeutics

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIO® (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade® (bortezomib) and dexamethasone for the treatment of patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for NEXPOVIO® (selinexor) for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.

Company profile

Ticker
KPTI
Exchange
Website
CEO
Michael Kauffman
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Karyopharm Securities Corp. • Karyopharm Europe GmbH • Karyopharm Therapeutics (Bermuda) Ltd. • Karyopharm Israel Ltd. ...
IRS number
263931704

KPTI stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

5 Aug 21
26 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 142.71M 142.71M 142.71M 142.71M 142.71M 142.71M
Cash burn (monthly) (positive/no burn) (positive/no burn) 17.82M 17.29M 18.58M 15.3M
Cash used (since last report) n/a n/a 69.33M 67.3M 72.32M 59.53M
Cash remaining n/a n/a 73.38M 75.41M 70.39M 83.18M
Runway (months of cash) n/a n/a 4.1 4.4 3.8 5.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
12 Jul 21 Jatin Shah Common Stock Payment of exercise Dispose F No No 9.73 665 6.47K 131,137
30 Jun 21 Sohanya Roshan Cheng Common Stock Grant Acquire A No No 0 7,500 0 7,500
30 Jun 21 Sohanya Roshan Cheng Nonstatutory Stock Option Common Stock Grant Acquire A No No 10.32 125,000 1.29M 125,000
2 Jun 21 Stephen Mitchener Common Stock Sell Dispose S No No 9.29 528 4.91K 2,472
1 Jun 21 Michael Mason Common Stock Grant Acquire A No No 0 5,500 0 57,255
1 Jun 21 Michael Mason Stock Option Common Stock Grant Acquire A No No 9.15 15,000 137.25K 15,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

77.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 149 166 -10.2%
Opened positions 21 28 -25.0%
Closed positions 38 28 +35.7%
Increased positions 51 56 -8.9%
Reduced positions 56 56
13F shares
Current Prev Q Change
Total value 599.99M 721.22M -16.8%
Total shares 58.14M 59.36M -2.1%
Total puts 1.3M 295.4K +338.6%
Total calls 312.9K 119.4K +162.1%
Total put/call ratio 4.1 2.5 +67.4%
Largest owners
Shares Value Change
BLK Blackrock 8.78M $90.62M +13.3%
STT State Street 5.82M $60.03M +9.1%
Palo Alto Investors 5.38M $55.55M +0.4%
Rubric Capital Management 4.25M $43.89M NEW
Vanguard 3.61M $37.29M +1.6%
Alkeon Capital Management 2.66M $27.48M -0.2%
Delphi Management Partners VIII, L.L.C. 2.26M $23.35M 0.0%
MS Morgan Stanley 1.64M $16.95M -3.3%
Frontier Capital Management 1.49M $15.37M +21.9%
Rice Hall James & Associates 1.41M $14.55M -9.8%
Largest transactions
Shares Bought/sold Change
Rubric Capital Management 4.25M +4.25M NEW
Adage Capital Partners GP, L.L.C. 0 -1.35M EXIT
Wellington Management 596K -1.32M -68.9%
BLK Blackrock 8.78M +1.03M +13.3%
Laurion Capital Management 60.79K -919.68K -93.8%
Compagnie Lombard Odier SCmA 0 -829.68K EXIT
Two Sigma Investments 846.12K -646.52K -43.3%
Millennium Management 115.01K -624.7K -84.5%
Citadel Advisors 211.09K -611.42K -74.3%
Lombard Odier Asset Management 1.38M +546.69K +65.9%

Financial report summary

?
Competition
PfizerAMGENCelgeneGeronRoche HoldingAstrazenecaRocheTG TherapeuticsSeagenArray
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: Africa, color, Contemporaneously, greyscale, HemaMax, inflow, interleukin, Korean, Libo, Ministry, Oceania, owe, Pharma, recombinant, standing, succeeded, unregistered, weekly
Removed: capitalization, capitalizing, deductibility, distributing, enact, expectation, FFCR, retroactively, succeed, temporarily, vigorously